RxDoctor Payments Data

Jack Gilbey, MD

Pulmonary Disease · Arlington, TXNPI 1922093426

Payments from drug & device makers

$927in general payments, 2019–2025

Across 52 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$415
  • AstraZeneca$114
  • Novartis$104
  • Grifols USA, LLC$58
  • Philips North America LLC$49
  • Insmed, Inc.$49
  • plus $139 from 5 others

What the payments were for

  • Food & beverage$927100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$927 in reported general payments places this provider in the 35th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$95,984
Medicare patients
344
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$150,951
Spiriva RespimatTiotropium Bromide47$55,613
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$55,292
SymbicortBudesonide/Formoterol Fumarate83$30,294
Stiolto RespimatTiotropium Br/Olodaterol Hcl41$28,692
Spiriva HandihalerTiotropium Bromide25$26,187
Breo ElliptaFluticasone/Vilanterol21$16,966
Advair HfaFluticasone Propion/Salmeterol34$16,418
Tiotropium Bromide17$11,971
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$11,381
EliquisApixaban13$11,084
Albuterol Sulfate HfaAlbuterol Sulfate323$10,530
Combivent RespimatIpratropium/Albuterol Sulfate11$10,440
Atrovent HfaIpratropium Bromide12$6,612
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$415$182,520190 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$40$94,74599 claims
AstraZenecaBreztri Aerosphere, Symbicort$114$85,585148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Arlington

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →